
|Podcasts|December 3, 2021
Pharmacy Focus: Psychedelic Pharmacy - Episode 2
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Advertisement
In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
4
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
5

















































































































































































































